How a CT-Direct Protocol at an American Comprehensive Stroke Center Led to Door-to-Needle Times Less Than 30 Minutes

Abstract

Background and Purpose:

The safety and efficacy of intravenous tissue plasminogen activator (IV tPA) following acute ischemic stroke (AIS) is dependent on its timely administration. In 2014, our Comprehensive Stroke Center designed and implemented a computed tomography-Direct protocol to streamline the evaluation process of suspected patients with AIS, with the aim of reducing door-to-needle (DTN) times. The objectives of our study were to describe the protocol development and implementation process, and to compare DTN times and symptomatic intracranial hemorrhage (sICH) rates before and after protocol implementation.

Methods:

Data were prospectively collected for patients with AIS receiving IV tPA between January 1, 2010, and May 31, 2015. The DTN times, examined as median times and time treatment windows, and sICH rates were compared pre- and postimplementation.

Results:

Two hundred ninety-five patients were included in the study. After protocol implementation, median DTN times were significantly reduced (38 vs 28 minutes; P < .001). The distribution of patients treated in the three time treatment windows described below changed significantly, with an increase in patients with DTN times of 30 minutes or less, and a decrease in patients with DTN times 31 to 60 minutes and over 60 minutes (P < .001). There were two cases of sICH prior to implementation and one sICH case postimplementation.

Conclusions:

The implementation of a protocol that streamlined the processing of suspected patients with AIS significantly reduced DTN time without negatively impacting patient safety.

Keywords

tissue-type plasminogen activator acute stroke ischemic stroke evidence-based medicine door-to-needle time

Get full access to this article

View all access options for this article.

References

Saver

. Time is brain—quantified. Stroke. 2006;37(1):263–266.

Marler

Tilley

. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649–1655.

Jauch

Saver

Adams

. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.

Fonarow

Smith

Saver

. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750–758.

Meretoja

Strbian

Mustanoja

Tatlisumak

Lindsberg

Kaste

. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306–313.

Menon

Saver

Prabhakaran

. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43(9):2293–2299.

American Heart Association and American Stroke Association. Campaign Manual: Target: Stroke Phase II. Texas, USA: American Stroke Association; 2014.

Moran

Nakagawa

Asai

Koenig

. 24/7 Neurocritical care nurse practitioner coverage reduced door-to-needle time in stroke patients treated with tissue plasminogen activator. J Stroke Cerebrovasc Dis. 2016;25(5):1148–1152.

Liang

Ren

Wang

. Effective management of patients with acute ischemic stroke based on lean production on thrombolytic flow optimization. Australas Phys Eng Sci Med. 2016;39(4):987–996.

10.

Liberman

Liotta

Caprio

. Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates? Neurol Clin Pract. 2015;5(3):247–252.

11.

Tsivgoulis

Zand

Katsanos

. Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis. Stroke J Cereb Circ. 2015;46(5):1281–1287.

12.

Nguyen

Chang

. Stroke mimics and acute stroke evaluation: clinical differentiation and complications after intravenous tissue plasminogen activator. J Emerg Med. 2015;49(2):244–252.